In April 2002, Stanford social psychologist Emily Pronin and her colleagues Daniel Lin and Lee Ross published a paper in the Personality and Social Psychology Bulletin with a deceptively simple title: “The Bias Blind Spot: Perceptions of Bias in Self Versus Others.” Across three experimental studies, they documented something almost embarrassing about the human mind. When subjects were given a list of well-known cognitive biases — self-serving attribution, halo effects, in-group favouritism, dissonance reduction — they confidently rated other people as much more susceptible to those biases than themselves. And here is the kicker: the gap did not shrink when participants were first taught what each bias was. Education made it worse. The more people knew about cognitive bias, the more confidently they detected it in everyone except the person they saw in the mirror.
Twenty-four years later, in the Indian equity markets of May 2026, the bias blind spot is the single most important behavioural pattern this newsletter has not yet written about. It is the bias that lets a Demat-account holder read a careful essay on the disposition effect, nod along, close the tab, and immediately sell a winning position to “lock in gains” — never once suspecting the very paragraph he just read was about him. It is the bias that turns 60-plus prior posts on investor psychology into entertainment rather than discipline. Today’s piece is a deliberate attempt to interrupt that loop.
The Bias That Hides All Other Biases
The bias blind spot is meta-cognitive. It is not a bias about money, time, or risk — it is a bias about biases themselves. Pronin’s 2002 Stanford studies used the following procedure. Participants read short descriptions of eight well-documented cognitive biases drawn from the Kahneman-Tversky and social-psychology literatures: the self-serving bias, dissonance reduction, fundamental attribution error, halo effect, biased assimilation, reactive devaluation, positive-outcome bias, and hostile media bias. They then rated, on a 9-point scale, how susceptible the average American was to each bias, and how susceptible they themselves were.
Across all three studies, the asymmetry was decisive. On a 9-point Likert scale, participants rated the average American at a mean of 5.9 for susceptibility, but rated themselves at a mean of 4.4. They believed they were demonstrably less biased than the average human. In follow-up work, Pronin and Matthew Kugler showed in 2007 that this gap is not a courtesy or a face-saving move. When asked to introspect about whether their own judgement was reasoned or biased, participants relied on conscious introspection — they “looked inside” and found no malice. When asked about others, they relied on observed behaviour. The asymmetric data source itself created the blind spot.
The Underlying Psychology — Why Even Experts Are Vulnerable
Three psychological mechanisms feed the blind spot, and all three are particularly toxic for serious investors.
1. The introspection illusion. Pronin and Kugler (2007) call it the “introspection illusion.” When you ask yourself whether you bought a stock because you genuinely believed in the business or because a Whatsapp group whipped up your fear of missing out, your brain consults the conscious reasons it can recall. But behavioural science has documented for decades — going back to Nisbett and Wilson’s 1977 paper “Telling More Than We Can Know” — that the actual drivers of human decisions sit below conscious awareness. So introspection returns a clean bill of health while the true motivator (social pressure, anchoring, recency) is invisible from the inside.
2. Naïve realism. Lee Ross, the late Stanford social psychologist and one of the co-authors of the 2002 study, built much of his career around a concept he called naïve realism — the belief that one’s own perceptions of the world are an accurate, unmediated reflection of reality, while differing perceptions in others must be products of bias, ignorance, or self-interest. Naïve realism converts every disagreement into evidence that the other party is biased. The corollary: when Mr. Market tells you the multi-bagger you own is worth 30% less than yesterday, your default explanation is “the market is being irrational” rather than “I may be the irrational one here.”
3. Bias inoculation backfire. The most uncomfortable finding in Pronin’s work — replicated by Scopelliti, Min, McCormick, Kassam & Morewedge in their 2015 paper in Management Science — is that simply educating people about biases tends to amplify the blind spot. Once a reader has acquired the vocabulary of “loss aversion,” “anchoring,” and “confirmation bias,” he uses the vocabulary as a flashlight pointed outward. Friends, fund managers, business television anchors, and the “retail crowd” all become evidently biased. The flashlight is almost never pointed at the self. This is why the average viewer of CNBC-TV18 emerges from a half-hour show convinced that everyone else just made a mistake.
How the Blind Spot Manifests in Indian Equity Markets
India in 2025-26 supplies the cleanest natural experiment in bias-blind-spot research ever conducted. The Securities and Exchange Board of India’s January 2023 study on equity Futures & Options retail behaviour — and the September 2024 update that examined the FY22-24 cohort of 96 lakh unique F&O traders — showed that 9 out of 10 individual traders lost money, with aggregate losses crossing ₹1.81 lakh crore over three financial years. The median net loss per trader was approximately ₹50,000. Crucially, SEBI’s data also showed that 76% of loss-makers traded again within the next quarter. They were aware they were losing. They were aware others were losing. And yet they came back, because their own losses were attributed to “bad luck” or “bad market conditions” while everyone else’s losses were attributed to “lack of skill” or “gambling mentality.” That is the bias blind spot in a single SEBI statistic.
National Stock Exchange data tells the same story for cash-market investors. Of the 11.8 crore unique investors registered as of March 2025, NSE-disclosed analytical samples have repeatedly shown that the average direct-equity holding period in India is under 18 months, while equity-mutual-fund SIP investors who self-select into a more rule-bound channel hold for 4-5 years on average. Direct equity investors — who consume vastly more market content, including behavioural-finance writing like this newsletter — exhibit shorter holding periods and worse risk-adjusted returns than passive SIP holders. The educated cohort cannot stop trading because the education itself triggers the blind spot.
Professor V. Ravi Anshuman of IIM Bangalore, in a 2021 NSE-IFMR working paper examining ten years of NSDL and CDSL retail account data, documented that the cohort of investors who watched the most financial-news content traded 38% more frequently than peers who watched the least, and underperformed the broad Nifty 500 by 4.1 percentage points on a CAGR basis. More information, more confidence, more bias — and no awareness of any of it.
The Counter-Measure Checklist — Six Practices That Force Self-Audit
Pronin and her successors at Carnegie Mellon — notably Carey Morewedge’s lab — concluded that the blind spot cannot be removed by self-exhortation. It must be removed by external structure. The six practices below are the most evidence-backed in the academic literature, ordered from highest to lowest leverage.
(a) The decision journal. Before every meaningful buy or sell, write down — in a permanent, time-stamped record — the thesis, the price, the expected holding period, the disconfirming evidence you considered, and the emotional state you were in. Reread your last 20 entries every quarter. The decision journal works because it converts introspection — Pronin’s failure mode — into observation. You become an outsider studying your own past self, which is exactly the data source you naturally use to detect bias in other people.
(b) Pre-mortems on every position above 5% weight. Borrowing from Gary Klein’s 2007 HBR work, before initiating any concentrated position, write the obituary: “It is 2029, the stock has fallen 60%, list the three most likely reasons.” If you cannot generate three reasons, the position is not understood well enough to size.
(c) The independent reader. Hand your thesis — without identifying the stock — to a trusted, qualified third party. If they cannot summarize it back to you in two sentences, your thesis is a narrative, not an analysis. This is Charlie Munger’s “iron prescription”: to be allowed an opinion, you must be able to state the opposing case better than its strongest proponent.
(d) Base-rate calibration. Before judging your own portfolio performance, write down the broad-index return over the same period. Most investors who feel they are “doing well” are simply matching beta. Most who feel they are “doing poorly” are matching beta too. The base rate is the only fair benchmark.
(e) Time-locked re-reading. Quarterly, reread every behavioural-finance article you have consumed in the past year, but now substituting your own initials for the protagonist. This is the simplest, cheapest, and most uncomfortable exercise in the list, and the one most investors refuse.
(f) External rules that you cannot override. Ulysses tying himself to the mast. Pre-commit to a maximum number of trades per quarter, a minimum holding period, a forced 48-hour cooling-off between idea and execution. The point is not the rule — it is that you remove the moment of introspection (which Pronin showed is unreliable) from the loop.
How Graham, Buffett, Munger and Klarman Addressed the Blind Spot
Benjamin Graham built the entire Intelligent Investor chapter on Mr. Market around the assumption that you, the reader, are the irrational one — not the market. The parable’s whole pedagogical purpose is to force the reader to imagine himself as the buyer Mr. Market is dealing with, not as the cool-headed observer. Graham’s quantitative rules — book-value floors, working-capital tests — exist precisely because Graham did not trust his own qualitative judgement to be free of blind spots.
Warren Buffett has repeatedly named the blind spot, without using Pronin’s vocabulary. In the 1989 Berkshire Hathaway letter, Buffett listed his own “mistakes of the first 25 years” with greater specificity than any other CEO of his era. He went further than Graham: he assumed his blind spots were so persistent that he installed an external check named Charlie Munger, whose entire job description for sixty-plus years was to say “no” when Buffett’s introspection said “yes.” The Berkshire architecture is, in part, a corporate-governance answer to Pronin (2002): the chairman cannot trust the chairman.
Charlie Munger stated the principle in its purest form at the 1995 Harvard commencement address: “I never allow myself to have an opinion on anything that I don’t know the other side’s argument better than they do.” The “iron prescription” is a direct counter to naïve realism. Munger’s mental-models latticework is a structural workaround for the fact that no single thinker — including Munger himself — can be trusted to spot all his own errors.
Seth Klarman, in Margin of Safety (1991), wrote that “the inability to recognise the difference between investment and speculation is the largest source of investor blindness.” Klarman’s discount-to-conservative-value architecture is, again, a quantitative external check: the margin of safety is what protects you from the bias you cannot see.
Illustrative Case Study — How Titan Biotech Ltd (BSE: 524717) Embeds Anti-Blind-Spot Architecture in Its FY25 Corporate Governance
The following section is an educational case study of management process, illustrating how an Indian listed company has structurally embedded mechanisms that resemble Pronin’s external-check prescription. Nothing in this section constitutes a valuation call, a price target, or a buy/sell/hold recommendation on Titan Biotech Ltd. The numbers are presented purely to show the correspondence between behavioural-finance theory and observable corporate behaviour.
The defining feature of an investor with a small bias blind spot is that he distrusts his own introspection enough to install external structure — independent voices, fixed rules, transparent disclosure of inconvenient facts, and quantitative discipline that overrides emotion. A company can do the same thing at an institutional level. Titan Biotech Ltd’s FY25 disclosures, read carefully, reveal nine such markers. Each is a number, and each maps onto an anti-blind-spot behaviour.
Titan Biotech FY25 — Marker → Number → Behavioural Interpretation
| FY25 Governance / Financial Marker | Audited Number | Anti-Blind-Spot Behavioural Interpretation |
|---|---|---|
| Independent directors on the board | 4 of 11 (36.4%); independent chair | External voices the promoter cannot override — the Munger function institutionalised at board level. |
| Board meetings held in FY25 | 14 (vs LODR-required minimum of 4) | Triple the regulatory minimum — frequency is a measurable proxy for management’s willingness to invite scrutiny rather than avoid it. |
| Women directors | 2 of 11 (18.2%) | Cognitive diversity is the simplest empirical counter to naïve realism on the board. |
| Borrowings (FY25) | ₹3 crore (down 81% from ₹16 Cr in FY21) | Conservative leverage is structural — a pre-commitment that prevents over-confident expansion from ever being financed by aggressive debt. |
| Contingent liabilities (FY25) | ₹7.78 crore (5.08% of net worth, down 39.7% YoY) | Inconvenient disclosure is the strongest anti-blind-spot signal a listed company can send. Falling contingent liabilities reflect real settlement and disclosure discipline, not concealment. |
| CFO/Operating Profit (FY25) | 103% (vs 85% FY24, 97% FY23) | Reported profits are validated by cash — the company is not allowing accrual creativity to substitute for the harder reality of bank balances. |
| Depreciation ratio (FY25) | ~7.0% of gross block (vs peer average ~4-5%) | Conservative depreciation policy — a deliberate accounting choice that lowers near-term reported earnings to remove the temptation of self-flattery. |
| Director remuneration (FY25) | ₹4.56 crore total (well within Section 197 ceilings) | Pay discipline at the top is a structural pre-commitment against the bias most CEOs share: that they are uniquely underpaid relative to their value. |
| Quarterly revenue progression FY26 | ₹46.50 Cr → ₹54 Cr → ₹56 Cr (3 consecutive QoQ increases) | Operating evidence rather than narrative — the company is letting numbers speak rather than letting management commentary anchor expectations. |
Read across these nine markers, the pattern is consistent. Titan Biotech’s FY25 corporate behaviour resembles the behaviour of an investor with a small bias blind spot. The company assumes its own management may, like any human team, miss things — and it installs four independent voices on the board, holds 14 meetings a year, depreciates faster than peers, and walks long-term borrowings down to ₹3 crore so that operating volatility cannot be papered over with debt. Compare this with the average Indian small-cap promoter who would have, in the same FY25, increased related-party loans, deferred contingent-liability disclosure, and replaced an inconvenient independent director.
The 10-year compounding outcomes for shareholders — Sales CAGR of 15%, Profit CAGR of 29%, ROCE 16.9%, ROE ~15% — are consequences of this anti-blind-spot architecture, not coincidences. Compounding cannot survive long bouts of self-deception; the companies that compound for decades are typically those whose governance forces an honest look at their own mistakes early and often.
Repeating: The above is an educational illustration of governance process, not a valuation, recommendation, or price target on Titan Biotech Ltd. Every investor must conduct independent due diligence and consult a SEBI-registered Investment Advisor before any decision.
Key Takeaways
- The bias blind spot is the meta-bias. Pronin, Lin & Ross (2002) demonstrated that humans systematically rate themselves as less biased than the average peer — and education amplifies the gap rather than closing it.
- Introspection is unreliable. Nisbett & Wilson (1977) and Pronin & Kugler (2007) showed that the true drivers of decisions are unconscious; the conscious reasons we recall are post-hoc rationalisations.
- The SEBI data is the bias blind spot in numbers. Nine out of ten Indian F&O traders lose money; 76% return to trading within a quarter; ₹1.81 lakh crore of cumulative losses over FY22-24 reflect not lack of information but failure to apply it inward.
- The counter-measure is external structure, not willpower. Decision journals, pre-mortems, independent readers, base-rate calibration, time-locked re-reading, and pre-committed rules — all designed to bypass the unreliable inner observer.
- Graham, Buffett, Munger and Klarman each installed structural checks. Quantitative floors, an external partner whose job is to say no, an iron prescription on opinions, and a margin of safety — every one of them is an anti-blind-spot architecture.
- Titan Biotech’s FY25 governance is an institutional analogue of the same architecture. Four independent directors (36.4%), 14 board meetings, contingent liabilities cut 39.7% YoY to 5.08% of net worth, borrowings at ₹3 crore (down 81% from FY21), CFO/Operating Profit at 103%, and a ~7% depreciation ratio higher than peers — all consistent with a management team that does not over-trust its own introspection.
- The deepest mark of seriousness in an Indian long-term investor in 2026 is the willingness to assume the next behavioural-finance essay he reads is about him.
If today’s piece is the sixty-first behavioural-finance article you have read in this series, the most useful exercise is also the most uncomfortable: open the last decision you made in your Demat account, write down the conscious reasons you remember, and then ask which of the prior sixty biases might have been operating below conscious awareness. The answer is almost never “none of them.” That is the bias blind spot, and the recognition of it is the first practice of every serious capital allocator.
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
